Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 273 results for obesity

  1. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

  2. Liposuction for chronic lipoedema (HTG618)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

  3. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  4. Accuro for guiding epidural or spinal anaesthesia (MIB245)

    NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .

  5. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

  6. Bariatric surgery in children and young people: What are the long-term outcomes of bariatric surgery in children and young people living with obesity?

    living with obesity? Any explanatory notes(if applicable) Source guidance details Comes from guidance Obesity:...

  7. Bipolar, schizophrenia and other psychoses: annual BMI recording (IND83)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM16

  8. Psychosis and schizophrenia in adults (QS80)

    This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.

  9. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

  10. Into practice resources

    Resources, case studies and patient decision aids to show how you can use evidence to improve care and services

  11. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  12. Physical activity: for NHS staff, patients and carers (QS84)

    This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.

  13. Diabetes: advice for erectile dysfunction (IND106)

    This indicator covers the percentage of male patients with diabetes who have a record of erectile dysfunction with a record of advice and assessment of contributory factors and treatment options in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM52